Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ALNY
stocks logo

ALNY

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
1.17B
+97.59%
1.290
-298.52%
1.22B
+105.87%
1.500
-440.91%
1.34B
+73.52%
1.752
-443.63%
Estimates Revision
The market is revising Upward the revenue expectations for Alnylam Pharmaceuticals, Inc. (ALNY) for FY2025, with the revenue forecasts being adjusted by 6.38% over the past three months. During the same period, the stock price has changed by 2.60%.
Revenue Estimates for FY2025
Revise Upward
up Image
+6.38%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+162.38%
In Past 3 Month
Stock Price
Go Up
up Image
+2.60%
In Past 3 Month
Wall Street analysts forecast ALNY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALNY is 504.24 USD with a low forecast of 370.00 USD and a high forecast of 583.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
23 Analyst Rating
Wall Street analysts forecast ALNY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALNY is 504.24 USD with a low forecast of 370.00 USD and a high forecast of 583.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Buy
4 Hold
0 Sell
Strong Buy
Current: 465.340
sliders
Low
370.00
Averages
504.24
High
583.00
Current: 465.340
sliders
Low
370.00
Averages
504.24
High
583.00
Wells Fargo
Tiago Fauth
Equal Weight
maintain
$395 -> $479
2025-11-11
Reason
Wells Fargo
Tiago Fauth
Price Target
$395 -> $479
2025-11-11
maintain
Equal Weight
Reason
Wells Fargo analyst Tiago Fauth raised the firm's price target on Alnylam to $479 from $395 and keeps an Equal Weight rating on the shares. The firm believes it may be hard for Alnylam to outperform in 2026. Wells sees a more balanced risk/reward, as Amvuttra estimates seem priced in at these levels. Competition and pricing narratives could also weigh on the stock, keeping it range bound, the firm adds.
Goldman Sachs
downgrade
2025-11-03
Reason
Goldman Sachs
Price Target
2025-11-03
downgrade
Reason
Goldman Sachs analysts removed Alnylam from the firm's US Conviction List as part of its monthly update.
Oppenheimer
Oppenheimer
maintain
$490 -> $500
2025-10-31
Reason
Oppenheimer
Oppenheimer
Price Target
$490 -> $500
2025-10-31
maintain
Reason
Oppenheimer raised the firm's price target on Alnylam to $500 from $490 and keeps an Outperform rating on the shares. The firm notes Amvuttra global revenue of $685M came just shy of its $690M but well ahead of the Street's $622M, and Alnylam raised full-year TTR franchise guidance by $275M at midpoint.
Chardan
Keay Nakae
Buy
maintain
$400 -> $475
2025-10-31
Reason
Chardan
Keay Nakae
Price Target
$400 -> $475
2025-10-31
maintain
Buy
Reason
Chardan analyst Keay Nakae raised the firm's price target on Alnylam to $475 from $400 and keeps a Buy rating on the shares following the Q3 report. The company's early sales trajectory of Amvuttra for ATTR-CM is "impressive," the analyst tells investors in a research note.
Barclays
Overweight
maintain
$460 -> $527
2025-10-31
Reason
Barclays
Price Target
$460 -> $527
2025-10-31
maintain
Overweight
Reason
Barclays raised the firm's price target on Alnylam to $527 from $460 and keeps an Overweight rating on the shares. The company reported another "strong beat and raise" quarter, but the stock traded down on narrowly missing buyside expectations, less robust guidance and a subpoena, the analyst tells investors in a research note. The firm's analysis of subpoena cases suggests "limited concern."
Piper Sandler
Edward Tenthoff
Overweight
maintain
$449 -> $489
2025-10-31
Reason
Piper Sandler
Edward Tenthoff
Price Target
$449 -> $489
2025-10-31
maintain
Overweight
Reason
Piper Sandler analyst Edward Tenthoff raised the firm's price target on Alnylam to $489 from $449 and keeps an Overweight rating on the shares. The firm notes AMVUTTRA sales of $685M in Q3 beat Street consensus driven by doubling of U.S. ATTR-CM revenues to $300M. Alnylam raised TTR revenue guidance to $2.475B-$2.525B in 2025, and Piper projects AMVUTTRA could grow to $3.9B in 2026.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Alnylam Pharmaceuticals Inc (ALNY.O) is 71.84, compared to its 5-year average forward P/E of -44.76. For a more detailed relative valuation and DCF analysis to assess Alnylam Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-44.76
Current PE
71.84
Overvalued PE
25.31
Undervalued PE
-114.84

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-7427.31
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
51083.71
Undervalued EV/EBITDA
-65938.33

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
15.56
Current PS
0.00
Overvalued PS
19.56
Undervalued PS
11.55
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ALNY News & Events

Events Timeline

(ET)
2025-11-09
12:09:00
Alnylam Reveals Findings from Post Hoc Analyses of HELIOS-B Phase 3 Trial
select
2025-10-30 (ET)
2025-10-30
09:31:23
Alnylam Announces Q3 Earnings Per Share of $1.84, Exceeding Consensus Estimate of $1.75
select
2025-10-01 (ET)
2025-10-01
07:32:43
Alnylam administers first dose to patient in ZENITH trial
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
12-04Barron's
S&P 500 Additions Coming This Friday: 9 Stocks Likely to Struggle.
  • Snowflake's Market Position: Snowflake is currently the largest company by market value that is not included in the S&P 500 index.
  • Profitability Concerns: The software provider is unlikely to be added to the S&P 500 due to its lack of profitability according to traditional accounting standards.
[object Object]
Preview
9.5
12-04Barron's
Snowflake and Other Major Software Firms Excluded from S&P 500 Due to Lack of Earnings

  • Snowflake's Market Position: Snowflake is currently the largest company by market value that is not included in the S&P 500 index.

  • Profitability Concerns: The software provider is unlikely to be admitted to the S&P 500 due to its lack of profitability according to traditional accounting standards.

[object Object]
Preview
2.0
12-04Barron's
Snowflake and Other Major Software Firms Excluded from S&P 500 Index
  • Snowflake's Market Position: Snowflake is currently the largest company by market value that is not included in the S&P 500 index.
  • Profitability Concerns: The software provider is unlikely to be added to the S&P 500 due to its lack of profitability according to traditional accounting standards.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Alnylam Pharmaceuticals Inc (ALNY) stock price today?

The current price of ALNY is 465.34 USD — it has decreased -1.68 % in the last trading day.

arrow icon

What is Alnylam Pharmaceuticals Inc (ALNY)'s business?

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.

arrow icon

What is the price predicton of ALNY Stock?

Wall Street analysts forecast ALNY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALNY is 504.24 USD with a low forecast of 370.00 USD and a high forecast of 583.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Alnylam Pharmaceuticals Inc (ALNY)'s revenue for the last quarter?

Alnylam Pharmaceuticals Inc revenue for the last quarter amounts to 1.25B USD, increased 149.35 % YoY.

arrow icon

What is Alnylam Pharmaceuticals Inc (ALNY)'s earnings per share (EPS) for the last quarter?

Alnylam Pharmaceuticals Inc. EPS for the last quarter amounts to 1.83 USD, decreased -310.34 % YoY.

arrow icon

What changes have occurred in the market's expectations for Alnylam Pharmaceuticals Inc (ALNY)'s fundamentals?

The market is revising Upward the revenue expectations for Alnylam Pharmaceuticals, Inc. (ALNY) for FY2025, with the revenue forecasts being adjusted by 6.38% over the past three months. During the same period, the stock price has changed by 2.60%.
arrow icon

How many employees does Alnylam Pharmaceuticals Inc (ALNY). have?

Alnylam Pharmaceuticals Inc (ALNY) has 2230 emplpoyees as of December 05 2025.

arrow icon

What is Alnylam Pharmaceuticals Inc (ALNY) market cap?

Today ALNY has the market capitalization of 61.48B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free